A Duke University study found that a common cholesterol drug, bezafibrate, can weaken ovarian cancer's natural defences, making existing treatments more effective. In advanced ovarian cancer, lipid (fats)-containing fluid called ascites often accumulates in the abdomen, which protects cancer cells. Bezafibrate was found to disrupt fat metabolism, making cancer cells far more susceptible to death.